Abstract 591P
Background
KRAS is the most commonly mutated oncogene in advanced, non-squamous, non-small cell lung cancer (nsqNSCLC). Tyrosine kinase inhibitors (TKIs)- sotorasib and adagrasib are approved for use in patients(pts) with KRASG12C variant. A novel TKIs- active in other KRAS variants are in development. Therefore all potentially targetable KRAS variants should be routinely tested in advanced NSCLC. The next generation sequencing (NGS) is recommended for simultaneous testing of potentially actionable biomarkers.
Methods
The study was performed as part of routine genetic diagnosis of pts with nsqNSCLC within a single institution between Jan.2019-May.2023. The material for the study consisted of tissue and cytologic samples containing no less than 20% of the tumor cells. The NGS method was used to assess the mutation status of the KRAS gene. Samples were sequenced using the FusionPlex CTL ArcherDx assay on a MiniSeq instrument (Illumina).
Results
In a group of 1468 real-world patients (pts) with advanced nsqNSCLC tested with NGS KRAS prevalence was 32,3% (474 pts). KRASG12C variant was observed in 229 pts representing 15,6% pts with nsqNSCLC and 48,3% of all KRAS mutant pts. In KRAS mutant group in cytological and tissue specimen the most common variants occurred accordingly in: Gly12Cys (50%, 48%), Gly12Asp (20%, 15%), Gly12Ala (9%, 8%), Gly12Val (14%, 15%), other variants less than 5% each (table). KRAS and other mutation coexisted in 7% (34 of 474) pts. The incidence of molecular KRAS variants diagnosed with NGS were comparable between the cytological and tissue specimen. Table: 591P
| Variant | All KRAS pts N=474 (100%) | Cytology N=88 (100%) | Tissue N=386 (100%) | |||
| N | % | N | % | N | % | |
| Gln61His | 20 | 4,22% | 2 | 2,27% | 18 | 4,7% |
| Gly12Ala | 40 | 8,44% | 8 | 9,09% | 32 | 8,3% |
| Gly12Asp | 75 | 15,82% | 18 | 20,45% | 57 | 14,8% |
| Gly12Cys | 229 | 48,31% | 44 | 50,00% | 185 | 47,9% |
| Gly12Val | 71 | 14,98% | 12 | 13,64% | 59 | 15,3% |
| Gly12Ser | 9 | 1,90% | 1 | 1,14% | 8 | 2,1% |
| Gln61Leu | 6 | 1,27% | 1 | 1,14% | 5 | 1,3% |
| exon2 | 8 | 1,69% | 1 | 1,14% | 7 | 1,8% |
| Gln61Lys | 7 | 1,48% | 1 | 1,14% | 6 | 1,6% |
| Gly12Phe | 4 | 0,84% | 0 | 0,00% | 4 | 1,0% |
| Gly12Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
| Lys117Asn | 1 | 0,21% | 0 | 0,00% | 1 | 0,3% |
| Gln61Arg | 2 | 0,42% | 0 | 0,00% | 2 | 0,5% |
Conclusions
The NGS is feasible for diagnosis of the KRAS mutations in real-world practice. The utility of both cytological and tissue testing is high for NGS profiling with comparable prevalence of the most frequent KRAS variants.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract